GHK-Cu + BPC-157 + TB-500 Information for Licensed U.S. Clinics
GHK-Cu, BPC-157, and TB-500 are peptide substances with different regulatory histories in the United States.
FDA evaluates these substances separately. Discussing or combining them under a commercial name such as “GLOW” does not create a separate FDA approval or establish that the combination qualifies for a particular compounding pathway.
Phoenix Meds Inc. provides licensed healthcare organizations with administrative support around documentation, credential review, and publicly available regulatory information.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About the GLOW Combination
The regulatory status of a multi-ingredient preparation depends on more than the name of the blend.
FDA’s current 503A materials distinguish non-injectable GHK-Cu from injectable GHK-Cu. As of May 14, 2026, GHK-Cu except for injectable routes is in Category 1 and remains under evaluation. That Category 1 designation does not extend to injectable GHK-Cu.
BPC-157 and TB-500 have separate FDA reviews. In July 2026, FDA proposed that the free-base and acetate forms of both substances not be included on the 503A Bulks List.
The FDA materials cited on this page evaluate GHK-Cu, BPC-157, and TB-500 separately. They should not be interpreted as establishing a separate FDA approval or 503A status for a three-ingredient preparation marketed as a ‘GLOW’ blend.
Phoenix therefore does not present the blend as an FDA-approved treatment or promote it for tissue repair, wound healing, recovery, inflammation, collagen production, anti-aging, sports injuries, or similar outcomes.
Why Route of Administration Matters
Route is especially important for GHK-Cu.
FDA currently places GHK-Cu except injectable routes in Category 1 under its interim 503A policy. FDA separately identifies injectable GHK-Cu among withdrawn nominations and notes potential immunogenicity concerns related to aggregation and peptide-related impurities.
For that reason, the non-injectable Category 1 status should not be used to imply that an injectable GHK-Cu-containing blend has the same regulatory position.
BPC-157 and TB-500 Considerations
FDA’s 2026 BPC-157 review states that neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug. FDA also identified limited safety information and concerns involving immunogenicity, peptide-related impurities, and API characterization.
For TB-500, FDA reported a lack of human-exposure data and identified potential immunogenicity concerns associated with aggregation and peptide-related impurities. FDA concluded that the available evidence weighed against adding TB-500 free base or acetate to the 503A Bulks List.
How Phoenix Meds Supports Licensed Clinics
Phoenix’s role is administrative.
We may help licensed healthcare organizations organize professional credentials, review available documentation, check publicly available regulatory records, and identify inconsistencies or questions that require review by the appropriate clinical, pharmacy, regulatory, or legal professional.
The purpose is to make the documentation easier to evaluate while keeping clinical and regulated medication activities with the parties responsible for them.
Phoenix’s review is not FDA approval, pharmacy accreditation, a clinical recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA identifies potential immunogenicity concerns involving aggregation and peptide-related impurities for compounded injectable GHK-Cu.
For BPC-157, FDA has identified potential immunogenicity concerns for certain routes of administration, along with concerns involving peptide-related impurities and API characterization.
For TB-500, FDA reported an absence of human exposure data and identified potential immunogenicity concerns for the proposed injectable routes.
GLOW Blend Administrative Review for Licensed Clinics
Clinic Verification
Professional and facility credentials may be reviewed as part of Phoenix’s administrative process.
Documentation Review
Phoenix may help organize available regulatory and supporting documentation so the clinic can identify matters requiring further professional review.
Licensed Parties
Any prescribing, compounding, dispensing, distribution, storage, shipping, or other regulated medication activity remains the responsibility of the party legally authorized to perform it.
Frequently Asked Questions
Is the GHK-Cu + BPC-157 + TB-500 combination FDA approved?
FDA materials reviewed for this page do not establish an FDA-approved drug product containing this three-ingredient combination.
Does GHK-Cu's Category 1 status apply to this injectable blend?
No. FDA’s current Category 1 listing expressly applies to GHK-Cu except for injectable routes of administration.
What is FDA's current position on BPC-157?
FDA evaluated BPC-157 free base and acetate in 2026 and proposed that neither be included on the 503A Bulks List.
What is FDA's current position on TB-500?
FDA evaluated TB-500 free base and acetate in 2026 and proposed that neither be included on the 503A Bulks List.
Does Phoenix Meds compound or dispense the GLOW blend?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of these substances.
What can Phoenix Meds help with?
Our work is administrative and may include credential review, organization of documentation, review of publicly available regulatory information, and professional communication.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present GHK-Cu, BPC-157, TB-500, or their combination as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.
Regulatory References
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act — Updated May 14, 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting
- FDA Briefing Document — BPC-157-Related Bulk Drug Substances (BPC-157 Free Base and BPC-157 Acetate)
- FDA Briefing Document — TB-500-Related Bulk Drug Substances (TB-500 Free Base and TB-500 Acetate)
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act